Biothera

Eagan, United States Founded: 1997 • Age: 29 yrs Acquired By Kerry Group
Gluco-polysaccharides are developed to engage innate immune systems against cancer.

About Biothera

Biothera is a Healthcare company based in Eagan (United States) founded in 1997, and was acquired by Kerry Group in October 2015. Gluco-polysaccharides are developed to engage innate immune systems against cancer. Biothera has raised $18.14 million across 3 funding rounds from investors including Kerry Group. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include BeiGene, C4 Therapeutics and Erasca; 3 of its 3 listed competitors have raised funding.

Company details

Biothera was founded in 1997 in Eagan, United States, within the biotechnology sector. Gluco-polysaccharides are developed by the company to direct innate immune responses toward cancer cells. The firm was previously named Biopolymer Engineering, with the name changed to Biothera in March 2005. Imprime PGG, the lead drug candidate, is under evaluation in clinical trials for metastatic colorectal cancer, non-small cell lung cancer, and chronic lymphocytic leukemia.

  • Headquarters Eagan, United States
  • Stage Acquired
  • Sectors
    Healthcare
  • Website biothera.com
  • Social LinkedIn
  • Acquired by Kerry Group (Oct 2015)
Key Metrics
  • Total Equity Funding
    $18.14M (USD)

    in 3 rounds

  • Latest Funding Round
    $14.64M (USD), Private Equity Round

    Mar 2018

  • Investors
  • Acquired by
    Kerry Group

    (Oct 2015)

Funding Insights of Biothera

Biothera has successfully raised a total of $18.14M across 3 strategic funding rounds. The most recent funding activity was a Private Equity Round of $14.64 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $18.14M
  • Total Rounds 3
  • Last Round Private Equity Round — $14.64M
  • First Round $3.5M

    (Apr 2010)

All 3 funding rounds of Biothera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2018$14.64MPrivate Equity Round––
–
Oct 2014Debt – Conventional––
–
Apr 2010$3.5MPrivate Equity Round––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Biothera

Biothera has secured backing from 1 investor. Prominent investors backing the company include Kerry Group.

All
InvestorDescriptionFounded YearDomainLocation
kerrygroup.com
Premium access

Investor details for Biothera

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Biothera

4 dated milestones of Biothera across 21 years, from founding to its latest funding, stage changes and deals.

  1. Founded Biothera is founded.
  2. Funding First funding round of $3.5M.
  3. Exit Acquired by Kerry Group.
  4. Funding Latest funding round, Private Equity Round, of $14.6M.

Competitors of Biothera

Biothera has 3 listed competitors in our database, 3 of them funded. They include BeiGene, C4 Therapeutics and Erasca.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
c4therapeutics.com2016Cambridge, United States$223M121
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
erasca.com2018San Diego, United States$300M120
Small molecule therapeutics for cancer treatment are developed.
Premium access

Detailed competitors of Biothera

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Biothera

Websites that share an audience with Biothera (biothera.com).

Similar websites

Websites whose visitors overlap most with Biothera. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
rspharmchem.com
rspharmchem.com
100%
–
aerokat.com
aerokat.com
61%
–
egyptianjournal.net78.net
egyptianjournal.net78.net
60%
–
wellmune.com
60%
2.2K#8,057,697View details
fortitechpremixes.com
60%
View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 10 similar websites and full traffic analytics for Biothera

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 10 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Biothera (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Biothera

Premium access

Complete news archive for Biothera

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Biothera

Biothera was founded in 1997 and raised its 1st funding round 13 years after it was founded.

Biothera is headquartered in Eagan, United States. It is registered at Eagan, Minnesota, United States.

Biothera is a funded company, having raised a total of $18.14M across 3 funding rounds to date. The company's 1st funding round was a Private Equity Round of $3.5M, raised on Apr 2010.

Biothera was founded in 1997 in Eagan, United States, within the biotechnology sector. Gluco-polysaccharides are developed by the company to direct innate immune responses toward cancer cells. The firm was previously named Biopolymer Engineering, with the name changed to Biothera in March 2005. Imprime PGG, the lead drug candidate, is under evaluation in clinical trials for metastatic colorectal cancer, non-small cell lung cancer, and chronic lymphocytic leukemia.

Biothera's top competitors include C4 Therapeutics, BeiGene and Erasca.

Biothera has 1 investor. Key investors include Kerry Group.

Yes. Biothera was acquired by Kerry Group in October 2015.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available